H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Benitec Biopharma (BNTC) to $32 from $35 and keeps a Buy rating on the shares. The firm cites the completed equity financing for the target cut.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTC:
- Benitec Biopharma: Strong Financial Position and Promising Clinical Developments Justify Buy Rating
- Citizens JMP healthcare analysts hold an analyst/industry conference
- Benitec Biopharma Reports Increased Quarterly Loss Amid Rising Expenses
- Benitec Biopharma reports Q1 EPS (22c), consensus (33c)
- Benitec Biopharma Announces $100 Million Public Offering